165 related articles for article (PubMed ID: 37437605)
1. Impact of radiation dose to the immune system on disease progression and survival for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
Wang X; Bai H; Gao M; Guan Y; Yu L; Li J; Dong Y; Song Y; Tao Z; Meng M; Wu Z; Zhao L; Yuan Z
Radiother Oncol; 2023 Sep; 186():109804. PubMed ID: 37437605
[TBL] [Abstract][Full Text] [Related]
2. Is a higher estimated dose of radiation to immune cells predictive of survival in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy?
Yin X; Luo J; Xu C; Meng C; Zhang J; Yu H; Liu N; Yuan Z; Wang P; Sun Y; Zhao L
Radiother Oncol; 2021 Jun; 159():218-223. PubMed ID: 33798612
[TBL] [Abstract][Full Text] [Related]
3. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
[TBL] [Abstract][Full Text] [Related]
4. [Prognosis Analysis of Early-stage Non-small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy].
Yu L; Li J; Gao M; Wang X; Bai H; Guan Y; Yuan Z
Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):274-280. PubMed ID: 37183642
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.
Cerra-Franco A; Liu S; Azar M; Shiue K; Freije S; Hinton J; Deig CR; Edwards D; Estabrook NC; Ellsworth SG; Huang K; Diab K; Langer MP; Zellars R; Kong FM; Wan J; Lautenschlaeger T
Clin Lung Cancer; 2019 May; 20(3):186-193.e3. PubMed ID: 30711394
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.
Zheng X; Sun Y; Ye K; Fan C; Wang X; Yang Y; Jiao R; Ge H
Thorac Cancer; 2021 Mar; 12(6):899-905. PubMed ID: 33529496
[TBL] [Abstract][Full Text] [Related]
7. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
8. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
Ricardi U; Frezza G; Filippi AR; Badellino S; Levis M; Navarria P; Salvi F; Marcenaro M; Trovò M; Guarneri A; Corvò R; Scorsetti M
Lung Cancer; 2014 Jun; 84(3):248-53. PubMed ID: 24681279
[TBL] [Abstract][Full Text] [Related]
10. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy for medically inoperable early-stage lung cancer: Tata Memorial Hospital perspective and practice recommendations.
Agarwal JP; Pilar A; Mummudi N; Gupta M; Laskar SG; Pathak RS; Tibdewal AR; Kinhikar R; Ghadi Y; Tandon S; Purandare N; Prabhash K; Patil V
Indian J Cancer; 2020; 57(1):18-24. PubMed ID: 31929233
[TBL] [Abstract][Full Text] [Related]
13. Lobar Gross Endobronchial Disease Predicts for Overall Survival and Grade 5 Pulmonary Toxicity in Medically Inoperable Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Aghdam N; Lischalk JW; Marin MP; Hall C; O'Connor T; Campbell L; Suy S; Collins SP; Margolis M; Krochmal R; Anderson E; Collins BT
Front Oncol; 2021; 11():728519. PubMed ID: 34912703
[TBL] [Abstract][Full Text] [Related]
14. Impact of Radiation Dose to Circulating Immune Cells on Tumor Control and Survival in Esophageal Cancer.
Cai S; Fan Y; Guo Q; Sun Y; Zhao P; Tian Y; Fan Q
Cancer Biother Radiopharm; 2023 Aug; 38(6):380-387. PubMed ID: 34883023
[No Abstract] [Full Text] [Related]
15. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
Yan SX; Qureshi MM; Dyer M; Truong MT; Mak KS
Lung Cancer; 2019 May; 131():147-153. PubMed ID: 31027693
[TBL] [Abstract][Full Text] [Related]
18. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric parameters related to occurrence of distant metastases and regional nodal relapse after SBRT for early-stage non-small cell lung cancer.
Lalonde R; Abdelhakiem M; Keller A; Huq MS
Radiother Oncol; 2022 Apr; 169():90-95. PubMed ID: 35202740
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of neutrophil-to-lymphocyte ratio change in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy.
Yin X; Chen H; Sun Y; Xiao L; Lu H; Guo W; Yang H; Zhou J; Fan K; Liang W
Sci Rep; 2024 May; 14(1):11984. PubMed ID: 38796631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
